Trials / Completed
CompletedNCT00283478
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Kentuckiana Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Detailed description
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iscar Quercus | |
| DRUG | Gemcitabine |
Timeline
- Start date
- 2004-05-01
- Completion
- 2007-04-01
- First posted
- 2006-01-30
- Last updated
- 2007-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00283478. Inclusion in this directory is not an endorsement.